{"id":53866,"date":"2025-10-23T08:00:00","date_gmt":"2025-10-23T06:00:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/stille-ab-publ-today-presents-the-report-for-the-third-quarter-2025\/"},"modified":"2025-10-23T08:00:00","modified_gmt":"2025-10-23T06:00:00","slug":"stille-ab-publ-today-presents-the-report-for-the-third-quarter-2025","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/stille-ab-publ-today-presents-the-report-for-the-third-quarter-2025\/","title":{"rendered":"Stille AB (publ) today presents the report for the third quarter 2025."},"content":{"rendered":"
\n

Revenue amounted to 138.8 MSEK (127.9), an increase of 8.5 percent, of which a negative organic growth of 1.9 percent. The quarter was negatively impacted by the phase-out of non-strategic products in surgical instruments that began in early 2025 and a negative currency effect. Adjusted for these two factors, underlying organic growth would have amounted to 7.3 percent.<\/strong><\/p>\n<\/div>\n

\n

\u201cWe had a continued strong demand and acquisition-driven sales growth in a quarter characterized by negative currency effects and stabilization of the supply chain<\/em>\u201d says Ulrik Berthelsen. \u201cLooking ahead to 2026, we anticipate a return to growth driven by a combination of strong order intake, operational improvements and commercial execution.<\/em>\u201d<\/p>\n

The gross profit margin in the quarter amounted to 48.8 percent (53.1) and EBIT before non-recurring items amounted to 17.3 MSEK (24.4).<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
MSEK<\/strong><\/td>\nJUL\u2013SEP<\/strong>
2025<\/strong><\/td>\n		JUL\u2013SEP<\/strong>
2024<\/strong><\/td>\n		JAN\u2013SEP 2025<\/strong><\/td>\nJAN\u2013SEP 2024<\/strong><\/td>\nOCT\u2013SEP 2024\/2025<\/strong><\/td>\nJAN\u2013DEC 2024<\/strong><\/td>\n<\/tr>\n
Net sales<\/td>\n138.8<\/td>\n127.9<\/td>\n392.7<\/td>\n408.7<\/td>\n554.0<\/td>\n569.9<\/td>\n<\/tr>\n
Gross profit, %<\/td>\n48.8<\/td>\n53.1<\/td>\n50.6<\/td>\n49.3<\/td>\n52.1<\/td>\n51.9<\/td>\n<\/tr>\n
EBITDA before non-recurring items<\/td>\n26.1<\/td>\n31.3<\/td>\n75.7<\/td>\n96.2<\/td>\n122.0<\/td>\n142.4<\/td>\n<\/tr>\n
EBITDA before non-recurring items, %<\/td>\n18.8<\/td>\n24.5<\/td>\n19.3<\/td>\n23.5<\/td>\n22.0<\/td>\n25.0<\/td>\n<\/tr>\n
EBITDA<\/td>\n19.0<\/td>\n31.3<\/td>\n68.6<\/td>\n76.1<\/td>\n90.5<\/td>\n98.0<\/td>\n<\/tr>\n
EBITDA, %<\/td>\n13.7<\/td>\n24.5<\/td>\n17.5<\/td>\n18.6<\/td>\n16.3<\/td>\n17.2<\/td>\n<\/tr>\n
EBIT before non-recurring items<\/td>\n17.3<\/td>\n24.4<\/td>\n51.8<\/td>\n75.7<\/td>\n91.0<\/td>\n114.9<\/td>\n<\/tr>\n
EBIT before non-recurring items, %<\/td>\n12.5<\/td>\n19.1<\/td>\n13.2<\/td>\n18.5<\/td>\n16.4<\/td>\n20.2<\/td>\n<\/tr>\n
EBIT<\/td>\n10.3<\/td>\n24.4<\/td>\n44.7<\/td>\n55.7<\/td>\n59.5<\/td>\n70.5<\/td>\n<\/tr>\n
EBIT, %<\/td>\n7.4<\/td>\n19.1<\/td>\n11.4<\/td>\n13.6<\/td>\n10.7<\/td>\n12.4<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

This information is information that Stille is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-10-23 08:00 CEST.<\/em><\/p>\n<\/div>\n

\n

Contact Details<\/strong>
Ulrik Berthelsen<\/strong>
CEO & President
+46 (0)73 033 38 25 | ulrik.berthelsen@stille.se<\/p>\n<\/div>\n

\n

About Us<\/strong>
Stille AB (publ) is a well-established pioneer in the development, manufacturing and distribution<\/strong> of premium surgical instruments and advanced surgical tables, with a differentiated offering in fast growing niche markets for high-precision procedures. Stille was founded in 1841 and is listed on Nasdaq First North Growth Market under the ticker \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, +46 8 684 211 10, adviser@eminova.se. More information is available at www.stille.se<\/a>.<\/p>\n<\/div>\n

\n

Attachments<\/strong>
Interim Report Stille Q3 2025<\/a><\/p>\n<\/div>\n